Subscribe
shutterstock_1349461187_pavel_kapysh
Pavel Kapysh / Shutterstock.com
16 December 2021AmericasAlex Baldwin

Intubated patients sedative patent the focus of ACS Dobfar suit

Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC approves Sun Pharma’s $4bn Ranbaxy merger
2 February 2015   The US Federal Trade Commission has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.


Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

Editor's picks

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025
Americas
Regeneron holds off copies of $6bn eye treatment
4 February 2025
Careers
Bristows appoints Irish patent attorney to boost UPC representation
4 February 2025
Americas
New national rankings recognise top US patent firms and lawyers
4 February 2025
Europe
UK court upholds EU SPC precedent, rejecting MSD’s appeal
30 January 2025
Americas
ADCs, TCR, and multimodal AI: Transformative trends in 2025
23 January 2025

More on this story

Americas
FTC approves Sun Pharma’s $4bn Ranbaxy merger
2 February 2015   The US Federal Trade Commission has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

More on this story

Americas
FTC approves Sun Pharma’s $4bn Ranbaxy merger
2 February 2015   The US Federal Trade Commission has given the green light for Sun Pharmaceutical to merge with Indian generic drug maker Ranbaxy for $4 billion.
Big Pharma
Court denies Sun Pharma’s bid to avoid trial
25 November 2021   Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

More features

Amy Candido to head IP litigation team at Simpson Thacher
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
The rise of weight loss drugs: Regulators tighten up
Paul Hastings adds Latham tech transactions expert as co-chair
Why Abbott’s victory marks a turning point for UPC preliminary injunctions
Natera loses $96m jury win as judge invalidates DNA test patents
Fed Circ’s Wuhan v ITC ruling opens ITC door to small corps
Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules